Overcoming Food Effects, Variability & Solubility For A Non-Opioid Analgesic With Lipid-Based Formulations

A client collaborated with Catalent to develop an optimized lipid-based formulation (LBF) for a poorly soluble oral small molecule that presented multiple development challenges, including significant food effects, high-dose requirements, solubility and stability concerns, and the need for rapid therapeutic onset.

Catalent’s approach focused on maximizing the concentration of the active pharmaceutical ingredient (API) while improving dispersibility to enhance absorption. Through a series of mechanistic in vitro studies, the team established a strong in vivo correlation, guiding formulation decisions with predictive, science-driven insights. The resulting LBF successfully minimized food-related variability, supported high-dose administration, and mitigated solubility and stability risks. This optimized formulation was ultimately selected for Phase 1 clinical trials, demonstrating how tailored lipid-based strategies can address complex oral delivery challenges and accelerate early-stage drug development.